Two people can receive the same fatty liver diagnosis but face very different health risks. One may have a relatively mild condition, while another could be more vulnerable to serious liver damage, heart disease or other complications. Scientists at Mayo Clinic have now identified five biologically distinct subtypes of metabolic dysfunction-associated steatotic liver disease (MASLD), offering a new way to understand why the disease progresses differently from person to person. The discovery could help doctors identify high-risk patients earlier, even when traditional warning signs are missing.
